This company listing is no longer active
GBI1 Stock Overview
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Genocea Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.052 |
| 52 Week High | US$1.77 |
| 52 Week Low | US$0.046 |
| Beta | 1.95 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.92% |
| 3 Year Change | -98.32% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBI1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -96.9% | -19.9% | 0.9% |
Return vs Industry: GBI1 underperformed the German Biotechs industry which returned -3.1% over the past year.
Return vs Market: GBI1 underperformed the German Market which returned -23.5% over the past year.
Price Volatility
| GBI1 volatility | |
|---|---|
| GBI1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GBI1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GBI1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 74 | Chip Clark | www.genocea.com |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.
Genocea Biosciences, Inc. Fundamentals Summary
| GBI1 fundamental statistics | |
|---|---|
| Market cap | €655.74k |
| Earnings (TTM) | -€37.04m |
| Revenue (TTM) | €1.90m |
0.3x
P/S Ratio0.0x
P/E RatioIs GBI1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBI1 income statement (TTM) | |
|---|---|
| Revenue | US$1.91m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.91m |
| Other Expenses | US$39.10m |
| Earnings | -US$37.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,946.15% |
| Debt/Equity Ratio | 61.7% |
How did GBI1 perform over the long term?
See historical performance and comparison